BRPI0910509A2 - composição farmacêutica, anticorpos, uso do anticorpo, polipeptídeos, polipeptídeo de cdr de cadeia pesada, polipeptídeo de cdr de cadeia leve e dna - Google Patents
composição farmacêutica, anticorpos, uso do anticorpo, polipeptídeos, polipeptídeo de cdr de cadeia pesada, polipeptídeo de cdr de cadeia leve e dnaInfo
- Publication number
- BRPI0910509A2 BRPI0910509A2 BRPI0910509A BRPI0910509A BRPI0910509A2 BR PI0910509 A2 BRPI0910509 A2 BR PI0910509A2 BR PI0910509 A BRPI0910509 A BR PI0910509A BR PI0910509 A BRPI0910509 A BR PI0910509A BR PI0910509 A2 BRPI0910509 A2 BR PI0910509A2
- Authority
- BR
- Brazil
- Prior art keywords
- chain cdr
- cdr polypeptide
- polypeptides
- antibodies
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-1800572008 | 2008-07-10 | ||
JP2008180057 | 2008-07-10 | ||
JP2009-0873792009 | 2009-03-31 | ||
JP2009087379 | 2009-03-31 | ||
PCT/JP2009/062573 WO2010005068A1 (ja) | 2008-07-10 | 2009-07-10 | 癌の治療及び予防用医薬組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0910509A2 true BRPI0910509A2 (pt) | 2015-09-29 |
BRPI0910509B1 BRPI0910509B1 (pt) | 2021-05-04 |
BRPI0910509B8 BRPI0910509B8 (pt) | 2021-05-25 |
Family
ID=41507178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0910509A BRPI0910509B8 (pt) | 2008-07-10 | 2009-07-10 | uso do anticorpo, anticorpo e composição farmacêutica |
Country Status (16)
Country | Link |
---|---|
US (2) | US10611835B2 (pt) |
EP (1) | EP2305300B1 (pt) |
JP (1) | JP5573156B2 (pt) |
KR (1) | KR101669834B1 (pt) |
CN (1) | CN102089004B (pt) |
AU (1) | AU2009270181B2 (pt) |
BR (1) | BRPI0910509B8 (pt) |
CA (1) | CA2730201C (pt) |
DK (1) | DK2305300T3 (pt) |
ES (1) | ES2575430T3 (pt) |
HU (1) | HUE028589T2 (pt) |
MX (1) | MX2011000117A (pt) |
PL (1) | PL2305300T3 (pt) |
PT (1) | PT2305300E (pt) |
RU (1) | RU2533460C2 (pt) |
WO (1) | WO2010005068A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6865688B2 (ja) | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ror1に特異的な抗体およびキメラ抗原受容体 |
AU2016249408A1 (en) | 2015-04-16 | 2017-11-09 | H. Lundbeck A/S. | Anti-PACAP antibodies and uses thereof |
PL3290051T3 (pl) * | 2015-04-30 | 2020-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi |
WO2017136607A1 (en) | 2016-02-02 | 2017-08-10 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
TWI770020B (zh) | 2016-04-15 | 2022-07-11 | 丹麥商H朗德貝克公司 | 人類化抗pacap 抗體及其用途 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2014073A (en) * | 1935-09-10 | Stovepipe | ||
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
AU640397B2 (en) | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
WO1999006541A1 (fr) * | 1997-07-29 | 1999-02-11 | Sumitomo Electric Industries, Ltd. | Anticorps du recepteur des cellules pre-b non humaines |
BR9909382A (pt) | 1998-04-03 | 2000-12-05 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado |
US6703360B2 (en) | 2000-04-07 | 2004-03-09 | Heska Corporation | Compositions and methods related to canine IgG and canine IL-13 receptors |
CA2469833C (en) | 2001-12-21 | 2008-05-20 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
WO2004024750A2 (en) | 2002-09-13 | 2004-03-25 | Dyax Corporation | Cd44-binding ligands |
US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
EP2960251A1 (en) * | 2003-05-09 | 2015-12-30 | Duke University | CD20-specific antibodies and methods of employing same |
JPWO2005083074A1 (ja) | 2004-03-01 | 2007-11-22 | 有限会社金沢大学ティ・エル・オー | 腫瘍抗原ペプチド |
KR100942849B1 (ko) | 2004-03-30 | 2010-02-17 | 글락소 그룹 리미티드 | 면역글로불린 |
US8999633B2 (en) | 2004-05-28 | 2015-04-07 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans |
JP4547197B2 (ja) | 2004-06-30 | 2010-09-22 | 公正 安元 | 癌特異的腫瘍抗原 |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
JP2007053501A (ja) | 2005-08-16 | 2007-03-01 | Matsushita Electric Ind Co Ltd | 管理装置、ip電話装置、ip電話システム及び更新方法 |
CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
AU2007254853B2 (en) * | 2006-06-02 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
WO2008034076A2 (en) * | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008034074A2 (en) * | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
WO2008141197A1 (en) | 2007-05-10 | 2008-11-20 | Sea Lane Biotechnologies, Llc | Chain reaction creating oligomers from repeat units of binding molecules |
CA2730088C (en) * | 2008-07-10 | 2020-04-14 | Toray Industries, Inc. | Immunity-inducing agent and method for detection of cancer |
TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
DK3342786T3 (en) * | 2010-01-29 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Anti-dll3-antistof |
NZ604510A (en) * | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
-
2009
- 2009-07-10 PT PT09794512T patent/PT2305300E/pt unknown
- 2009-07-10 WO PCT/JP2009/062573 patent/WO2010005068A1/ja active Application Filing
- 2009-07-10 ES ES09794512.5T patent/ES2575430T3/es active Active
- 2009-07-10 US US13/002,636 patent/US10611835B2/en active Active
- 2009-07-10 JP JP2009530726A patent/JP5573156B2/ja active Active
- 2009-07-10 DK DK09794512.5T patent/DK2305300T3/en active
- 2009-07-10 KR KR1020107029569A patent/KR101669834B1/ko active IP Right Grant
- 2009-07-10 AU AU2009270181A patent/AU2009270181B2/en active Active
- 2009-07-10 MX MX2011000117A patent/MX2011000117A/es active IP Right Grant
- 2009-07-10 BR BRPI0910509A patent/BRPI0910509B8/pt active IP Right Grant
- 2009-07-10 PL PL09794512.5T patent/PL2305300T3/pl unknown
- 2009-07-10 EP EP09794512.5A patent/EP2305300B1/en active Active
- 2009-07-10 CA CA2730201A patent/CA2730201C/en active Active
- 2009-07-10 CN CN200980126629.8A patent/CN102089004B/zh active Active
- 2009-07-10 HU HUE09794512A patent/HUE028589T2/en unknown
- 2009-07-10 RU RU2011104709/15A patent/RU2533460C2/ru active
-
2020
- 2020-02-25 US US16/800,852 patent/US11993650B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2009270181B2 (en) | 2014-05-29 |
PT2305300E (pt) | 2016-06-16 |
PL2305300T3 (pl) | 2016-09-30 |
EP2305300A1 (en) | 2011-04-06 |
US20110129478A1 (en) | 2011-06-02 |
EP2305300B1 (en) | 2016-04-06 |
US20200247888A1 (en) | 2020-08-06 |
EP2305300A4 (en) | 2011-11-02 |
RU2011104709A (ru) | 2012-08-20 |
CN102089004B (zh) | 2018-06-01 |
JP5573156B2 (ja) | 2014-08-20 |
BRPI0910509B8 (pt) | 2021-05-25 |
CA2730201C (en) | 2019-02-05 |
CA2730201A1 (en) | 2010-01-14 |
KR20110039423A (ko) | 2011-04-18 |
ES2575430T3 (es) | 2016-06-28 |
US11993650B2 (en) | 2024-05-28 |
US10611835B2 (en) | 2020-04-07 |
HUE028589T2 (en) | 2016-12-28 |
AU2009270181A1 (en) | 2010-01-14 |
MX2011000117A (es) | 2011-02-25 |
JPWO2010005068A1 (ja) | 2012-01-05 |
DK2305300T3 (en) | 2016-06-06 |
KR101669834B1 (ko) | 2016-10-27 |
WO2010005068A1 (ja) | 2010-01-14 |
CN102089004A (zh) | 2011-06-08 |
BRPI0910509B1 (pt) | 2021-05-04 |
RU2533460C2 (ru) | 2014-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190312T1 (hr) | Vežući proteini, uključujući protutijela, derivate protutijela i fragmente protutijela, koji se specifično vežu na cd154 i njihova upotreba | |
CY2023018I1 (el) | Συνθεσεις αντισωματων anti-ctla-4 | |
BRPI1005322A2 (pt) | anticorpo, composição farmacêutica e uso de pelo menos um anticorpo | |
BRPI0820543A2 (pt) | Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo | |
BRPI0924177A2 (pt) | Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso | |
BRPI0818437A2 (pt) | Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma | |
BRPI0812400A2 (pt) | Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade. | |
CU23869B1 (es) | Anticuerpos anti-esclerostina y proteínas funcionales | |
BRPI0905076A2 (pt) | Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo | |
BRPI0918947A2 (pt) | proteína de fusão de anticorpo | |
BRPI0821447A2 (pt) | Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea | |
SI2162467T1 (sl) | Polipeptidi, protitelesne variabilne domene in antagonisti | |
BRPI0906478A2 (pt) | anticorpo anti-nr10 e uso do mesmo | |
BRPI0715989A8 (pt) | "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" | |
BRPI0807480A2 (pt) | Ligando, imunoglobulina g, composição e proteína de fusão | |
CL2014000400A1 (es) | Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11). | |
IL201399A0 (en) | Polypeptides, antibody variable domains and antagonists | |
BRPI0923199A2 (pt) | métodos e composições para detecção de anticorpos com fixação de complemento. | |
BRPI0819210A2 (pt) | Anticorpos de proteína g anti-rsv | |
BRPI0811637A2 (pt) | Proteínas de fusão da imunoglobina | |
BRPI0807118A2 (pt) | Material, uso de um material, dispositivo de emissão de luz, e, sistema. | |
DK2185574T3 (da) | Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner | |
DK2031987T3 (da) | Syrnede proteindrikke, der indeholder suspenderede partikulære materialer, og fremgangsmåder til fremstilling heraf | |
BRPI0814127A2 (pt) | Polipeptídeos imunegênicos e anticorpos monoclonais | |
DK2171060T3 (da) | Superagonistisk anti-CD28-antistof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |